Technology alone will not answer that need
En Madrid, líderes del sector sanitario español se reunieron para explorar una de las tensiones más profundas de la medicina contemporánea: cómo integrar la inteligencia artificial sin sacrificar la dimensión humana que da sentido al cuidado. El debate reveló que la tecnología avanza más rápido que las estructuras que deben gobernarla, y que España invierte apenas un 4% de su gasto sanitario en tecnología, una cifra que pone en duda la capacidad del sistema para cumplir las promesas de la medicina personalizada. Lo que está en juego no es solo eficiencia, sino el tipo de sistema de salud —y de sociedad— que el país quiere construir.
- La inteligencia artificial ha dejado de ser una promesa futura para convertirse en una infraestructura necesaria, pero el marco regulatorio y la inversión tecnológica en España no han seguido el mismo ritmo.
- Con solo el 4% del gasto sanitario destinado a tecnología, el sector advierte que la brecha entre lo que la ciencia puede ofrecer y lo que el sistema puede sostener se está ensanchando peligrosamente.
- Una ley farmacéutica sin revisar en dos décadas y una normativa de salud digital aún en consulta pública generan incertidumbre sobre quién controla los datos médicos y cómo se financiarán las terapias avanzadas.
- Los expertos insisten en que la automatización no debe deshumanizar la atención: liberar a los profesionales de tareas rutinarias es precisamente lo que les permite dedicarse a la relación médico-paciente.
- El sector busca un equilibrio difícil: adoptar nuevas tecnologías con velocidad suficiente para no quedarse atrás, pero con la gobernanza necesaria para garantizar equidad, seguridad y acceso universal.
En el VI Simposio del Observatorio de la Sanidad celebrado en Madrid, cuatro voces representativas del ecosistema sanitario español debatieron bajo el título 'Una nueva forma de entender la salud'. El punto de partida fue compartido: la medicina atraviesa una revolución biomédica y tecnológica, pero las estructuras que la gobiernan —precios, aprobaciones, financiación— no han evolucionado al mismo ritmo.
Juan Yermo, de la patronal farmacéutica, reclamó una actualización urgente de los marcos de gobernanza para que la medicina personalizada pueda desplegarse con garantías. Manuel Ángel Galván, representando a los farmacéuticos, añadió que cualquier transformación debe ser integral: alcanzar la prevención, reducir las desigualdades regionales en los programas de cribado y, sobre todo, mantener la cercanía con el ciudadano. La tecnología, advirtió, no puede sustituir esa proximidad.
Marta Villanueva, directora de la Fundación IDIS, describió la inteligencia artificial como un nuevo compañero de viaje para los profesionales sanitarios: útil para automatizar tareas administrativas y diagnósticas, valioso para amplificar el conocimiento clínico, pero incapaz de reemplazar la dimensión humana del cuidado. Reconoció también que el sector navega en una incertidumbre genuina: muchas preguntas que parecían resueltas han vuelto a abrirse.
Pablo Crespo, de la industria tecnosanitaria, puso cifras al desafío: 146 millones de euros invertidos en tecnología el año pasado, apenas el 4% del gasto sanitario total. Si España aspira a incorporar terapias precisas e inteligencia artificial a escala, señaló, la estrategia de inversión debe revisarse desde sus cimientos.
El debate también abordó una ley farmacéutica sin actualización sustancial en veinte años y un borrador de ley de salud digital en consulta pública hasta el 20 de octubre. Esta última busca establecer quién controla los historiales médicos en un sistema fragmentado entre lo público y lo privado, y cómo pueden usarse los datos para la investigación. Sin interoperabilidad y reglas claras, advirtió Villanueva, el potencial de la IA en medicina seguirá siendo teórico.
Lo que el simposio dejó no fue consenso, sino una conciencia compartida: las herramientas existen, la necesidad es evidente, pero queda por ver si las instituciones, la inversión y la voluntad política pueden moverse a la velocidad que la tecnología exige.
At the sixth annual Healthcare Observatory Symposium in Madrid, a panel of industry leaders gathered to discuss a question that has begun to reshape medicine across Spain: how to harness artificial intelligence without losing the human touch that defines good care.
The conversation, titled "A New Way of Understanding Health," brought together four voices from different corners of the healthcare ecosystem. Juan Yermo, who leads the pharmaceutical manufacturers' association, opened by framing the moment as a biomédical and technological revolution. The systems that govern how medicines are priced, approved, and paid for, he argued, have not kept pace with what science can now deliver. Without updating those governance structures, the sector risks falling behind the possibilities of personalized medicine.
Manuel Ángel Galván, representing Spain's pharmacists, echoed the call for systemic change but grounded it differently. He spoke of the need for an integral revolution—one that reaches into prevention and screening programs, which he noted remain uneven across Spain's regional health systems. But he also sounded a note of caution: any transformation must bring citizens and companies along. People need more closeness with their healthcare providers, he said. Technology alone will not answer that need.
Marta Villanueva, director of the IDIS Foundation, named what many in the room were circling around: artificial intelligence as a new traveling companion for healthcare. She described AI's practical value—automating routine administrative and diagnostic work, freeing professionals to focus on what machines cannot do: the human dimensions of care, the amplification of clinical knowledge, the relationship between doctor and patient. But she also acknowledged something harder to quantify: the sector is entering a moment of genuine uncertainty. Questions that seemed settled no longer are. Many new ones have no clear answers yet.
Pablo Crespo, speaking for the medical technology industry, brought the conversation to ground with a stark number. Spain's healthcare system spent 146 million euros on technology investment last year. That sounds substantial until you learn it represents just 4 percent of total healthcare spending. If the country wants a healthcare system capable of delivering precise therapies and incorporating tools like artificial intelligence, Crespo suggested, the first question should be whether the investment strategy actually supports that ambition.
The panel also addressed a pending pharmaceutical law that has not been substantially revised in two decades. Yermo called the current draft complicated but expected it would evolve toward something offering more predictability for manufacturers and more gradual transitions for off-patent medicines. Crespo flagged a specific risk: a cost-control measure currently limited to pharmacy-dispensed drugs could expand into hospital settings, potentially threatening supply chains. Galván acknowledged the law's necessity while insisting it must balance efficiency and competitiveness against safety, equity, and universal access to medicines.
A separate initiative—a draft digital health law with a public comment period extending to October 20—aims to establish who controls medical records across Spain's fragmented private and public systems and how patient data can be used for research. Villanueva emphasized that governance must prevent the healthcare data landscape from splintering into isolated silos. The stakes are high: without interoperability and clear rules, the promise of AI-driven insights and personalized medicine remains theoretical.
What emerged from the discussion was not consensus but a shared recognition that Spanish healthcare stands at an inflection point. The tools exist. The need is clear. What remains uncertain is whether the institutions, the investment, and the will to change can move at the speed the technology demands.
Citas Notables
We are living through a biomedical and technological revolution. Legislation, governance, and tools must evolve to match the opportunities of personalized medicine.— Juan Yermo, director general of FarmaIndustria
AI serves us for automating processes so we can dedicate ourselves to what truly adds value—humanization by professionals—and it amplifies our knowledge.— Marta Villanueva, director general of the IDIS Foundation
La Conversación del Hearth Otra perspectiva de la historia
When these leaders talk about AI as a "traveling companion," what do they actually mean by that?
They mean AI should handle the work that doesn't require judgment or presence—sorting data, flagging patterns, managing schedules. That frees doctors and nurses to do what only humans can: listen, decide, reassure. It's a division of labor, not a replacement.
But Spain invests only 4 percent of its healthcare budget in technology. How do you build that kind of system on such a thin foundation?
You don't, really. That's the tension. They're describing a future that requires serious money, but the current spending suggests the system isn't ready to commit to it. It's like planning a high-speed rail network while still funding horse carriages.
The pharmaceutical law hasn't been updated in twenty years. Why does that matter for AI?
Because AI works best when data flows freely and rules are clear. If the law doesn't address how medicines are priced, approved, and tracked in a digital world, you can't build the systems you need. You're trying to run modern medicine through outdated plumbing.
What's the real fear underneath all this talk about humanization?
That efficiency becomes the only metric. That we optimize for speed and cost and forget that healthcare is fundamentally about vulnerability—people at their worst, needing someone who sees them. AI can't do that. But if the system is structured to reward what AI does well, the human part gets squeezed out.
So what has to happen next?
The law has to pass. Investment has to increase. And someone has to actually design systems where the technology serves the care, not the other way around. Right now, it's all aspiration. The hard part is the implementation.